103 related articles for article (PubMed ID: 37875426)
1. [A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese patients with advanced solid tumors].
Liu RR; Gu SZ; Zhou T; Lin LZ; Chen WC; Zhong DS; Liu TS; Yang N; Shen L; Xu SY; Lu N; Zhang Y; Gong ZL; Xu JM
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):898-903. PubMed ID: 37875426
[No Abstract] [Full Text] [Related]
2. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Shimizu T; Nakajima TE; Yamamoto N; Yonemori K; Koyama T; Kondo S; Sunakawa Y; Izawa N; Horie Y; Xiang S; Xu S; Qin L; Gong J; Liu D
Invest New Drugs; 2022 Oct; 40(5):1021-1031. PubMed ID: 35932387
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Harb W; Peer CJ; Hua Q; Xu S; Lu H; Lu N; He Y; Xu T; Dong R; Gong J; Liu D
Oncologist; 2021 Sep; 26(9):e1514-e1525. PubMed ID: 33973293
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
5. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
6. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.
Chen M; Jiang M; Wang X; Shen L; Li J
Expert Opin Biol Ther; 2022 Oct; 22(10):1227-1232. PubMed ID: 36124972
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
[TBL] [Abstract][Full Text] [Related]
8. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
9. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
13. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.
Luo Y; Cheng Y; Wu C; Ye H; Chen N; Zhang F; Wei H; Xu B
Invest New Drugs; 2023 Jun; 41(3):503-511. PubMed ID: 37171721
[TBL] [Abstract][Full Text] [Related]
15. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
[TBL] [Abstract][Full Text] [Related]
16. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors.
Zhang C; Li J; Wu H; Huang W; Da L; Shen Y; Sun G
Front Pharmacol; 2024; 15():1356013. PubMed ID: 38357311
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
19. TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study.
Xue J; Xue L; Tang W; Ge X; Zhao W; Li Q; Peng W; Dai C; Guo Y; Li J
Ther Adv Med Oncol; 2024; 16():17588359231220516. PubMed ID: 38188467
[TBL] [Abstract][Full Text] [Related]
20. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
